Related Experiment Video
Updated: Apr 10, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
35.0K
CLPTM1L polymorphism and lung cancer risk
Min Tang1, Xiaonian Bian1, Qiuliang Zhao1
1Department of Respiratory Medicine, 101st Hospital of People's Liberation Army Wuxi 214044, Jiangsu, China.
Summary
The Cleft Lip and Palate Transmembrane Protein 1 (CLPTM1L) rs31489 polymorphism is linked to increased lung cancer risk overall. This association is significant in Caucasians but not in Asians.
Area of Science:
- Genetics and Genomics
- Oncology
- Molecular Biology
Background:
- The Cleft Lip and Palate Transmembrane Protein 1 (CLPTM1L) rs31489 polymorphism's association with lung cancer risk is debated.
- Previous studies have yielded conflicting results, necessitating a comprehensive meta-analysis.
Purpose of the Study:
- To investigate the association between the CLPTM1L rs31489 polymorphism and lung cancer risk.
- To clarify the controversial findings through a meta-analysis of existing studies.
Main Methods:
- A systematic literature search was conducted across multiple databases (PubMed, Embase, Web of Science, etc.).
- Studies examining the CLPTM1L rs31489 polymorphism and lung cancer risk were included.
- Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the strength of association.
Main Results:
- Overall analysis revealed a significant association between CLPTM1L rs31489 polymorphism and lung cancer risk (OR = 1.12; 95% CI, 1.06-1.18).
- Subgroup analysis by ethnicity showed a statistically increased cancer risk in Caucasians (OR = 1.15; 95% CI, 1.10-1.21).
- No significant association was found in the Asian population (OR = 1.03; 95% CI, 0.97-1.08).
Conclusions:
- The CLPTM1L rs31489 polymorphism significantly modifies lung cancer risk.
- The genetic association is ethnicity-dependent, with a notable impact on Caucasian populations.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
122
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
122
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
147
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
147
03:18Non-LTR Retrotransposons
14.1K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
14.1K
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
74
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
74
02:39lncRNA - Long Non-coding RNAs
10.2K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K